Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, Thomas F., Zhao, Fangzhu, Huang, Deli, Beutler, Nathan, Burns, Alison, He, Wan-ting, Limbo, Oliver, Smith, Chloe +26 more·2020·Science
DOI 10.1126/science.abc7520

Cited by (1,034)

Items 301–400 of 1,034

  1. Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection
    Yu-Di Zhang, Q. Yan, K. Luo, P. He, Rui-Tian Hou, Xinwei Zhao, Qian Wang, Haisu Yi, Huan Liang, Yijun Deng et al. · 2021 · Journal of Virology
  2. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
    Cong Zeng, John P. Evans, Julia N Faraone, Panke Qu, Yi-Min Zheng, L. Saif, Eugene M. Oltz, G. Lozanski, Richard J. Gumina, Shan-Lu Liu · 2021 · mBio
  3. Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2
    L. Grandjean, Anja Saso, Arturo Torres Ortiz, T. Lam, J. Hatcher, Rosie Thistlethwayte, M. Harris, T. Best, Marina Johnson, H. Wagstaffe et al. · 2021 · Clinical Infectious Diseases
  4. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum
    S. Fiedler, Monika A. Piziorska, Viola Denninger, A. Morgunov, A. Ilsley, Anisa Y. Malik, Matthias M. Schneider, S. Devenish, G. Meisl, V. Kosmoliaptsis et al. · 2021 · ACS Infectious Diseases
  5. Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test
    J. Heggestad, David S. Kinnamon, Lyra B. Olson, Jason Liu, Garrett Kelly, Simone A. Wall, Solomon Oshabaheebwa, Zachary Quinn, C. Fontes, D. Joh et al. · 2021 · Science Advances
  6. Immunity to SARS-CoV-2: Lessons Learned
    JAIME E. FERGIE, Amit K. Srivastava · 2021 · Frontiers in Immunology
  7. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
    C. Beltrán-Pavez, S. Riquelme-Barrios, A. Oyarzún-Arrau, A. Gaete-Argel, R. González-Stegmaier, Karina Cereceda-Solis, A. Aguirre, D. Travisany, R. Palma-Véjares, Gonzalo P. Barriga et al. · 2021 · Science Advances
  8. No Evidence for Human Monocyte-Derived Macrophage Infection and Antibody-Mediated Enhancement of SARS-CoV-2 Infection
    Obdulio García-Nicolás, Philip V’kovski, Ferdinand Zettl, Gert Zimmer, Volker Thiel, Artur Summerfield · 2021 · Frontiers in Cellular and Infection Microbiology
  9. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria
    Egon A. Ozer, Lacy M. Simons, O. M. Adewumi, A. Fowotade, E. Omoruyi, J. Adeniji, O. A. Olayinka, Taylor J Dean, Janet P Zayas, Pavan P. Bhimalli et al. · 2022 · Nature Communications
  10. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems
    Iuliia A. Merkuleva, D. Shcherbakov, M. B. Borgoyakova, D. Shanshin, A. P. Rudometov, L. Karpenko, S. Belenkaya, A. A. Isaeva, V. S. Nesmeyanova, E. Kazachinskaia et al. · 2022 · Vaccines
  11. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
    David R. Martinez, A. Schäfer, S. Leist, Da-Peng Li, K. Gully, B. Yount, Joy Y. Feng, Elaine Bunyan, D. Porter, T. Cihlář et al. · 2021 · Cell Reports
  12. COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
    G. Novelli, M. Biancolella, R. Mehrian-Shai, V. Colona, A. Brito, N. Grubaugh, V. Vasiliou, L. Luzzatto, J. Reichardt · 2021 · Human Genomics
  13. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
    Qiu‐Yan Xu, Jian-Hang Xue, Yao Xiao, Zhi-Juan Jia, Mengjuan Wu, Yan‐Yun Liu, Wei-Li Li, Xianming Liang, Tian‐Ci Yang · 2021 · Frontiers in Immunology
  14. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
    I. Abela, C. Pasin, Magdalena Schwarzmüller, Selina Epp, M. Sickmann, M. Schanz, P. Rusert, J. Weber, S. Schmutz, A. Audigé et al. · 2021 · Nature Communications
  15. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants
    V. Upadhyay, A. Lucas, Sudipta Panja, Ryuki Miyauchi, Krishna M. G. Mallela · 2021 · Journal of Biological Chemistry
  16. One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
    Irene M. Francino Urdániz, Paul J. Steiner, Monica B Kirby, Fang-Zhu Zhao, Cyrus M. Haas, Shawn Barman, Emily R. Rhodes, Linghang Peng, K. Sprenger, J. Jardine et al. · 2021 · bioRxiv
  17. On the road to ending the COVID-19 pandemic: Are we there yet?
    J. Case, Emma S. Winkler, J. Errico, Michael S. Diamond · 2021 · Virology
  18. Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
    C. Chakraborty, M. Bhattacharya, A. R. Sharma · 2021 · Current opinion in pharmacology (Print)
  19. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
    Yongbing Pan, Jian-Hui Du, Jia Liu, Hai Wu, Fang Gui, Nan Zhang, Xiao-Jie Deng, Gang Song, Yufeng Li, Jia Lu et al. · 2021 · Cell Discovery
  20. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
    Dung Nguyen, P. Simmonds, M. Steenhuis, Elise Wouters, Daniel Desmecht, M. Garigliany, M. Romano, Cyril Barbezange, P. Maes, B. Van Holm et al. · 2021 · Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  21. Evaluation of the Ability of AlphaFold to Predict the Three-Dimensional Structures of Antibodies and Epitopes
    Polonsky, Ksenia, Pupko, Tal, Freund, Natalia T · 2023
  22. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
    Muecksch, Frauke, Weisblum, Yiska, Barnes, Christopher O., Schmidt, Fabian, Schaefer-Babajew, Dennis, Lorenzi, Julio C C, Flyak, Andrew I, DeLaitsch, Andrew T, Huey-Tubman, Kathryn E, Hou, Shurong et al. · 2021
  23. Prospects of Neutralizing Nanobodies Against SARS-CoV-2
    Fangfang Chen, Zhihong Liu, Fan Jiang · 2021 · Frontiers in Immunology
  24. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
    R. Goupil, M. Benlarbi, W. Beaubien-Souligny, Annie-Claire Nadeau-Fredette, D. Chatterjee, G. Goyette, L. Gunaratnam, Caroline Lamarche, A. Tom, A. Finzi et al. · 2021 · Canadian Medical Association Journal
  25. A Single-Cell Atlas of Lymphocyte Adaptive Immune Repertoires and Transcriptomes Reveals Age-Related Differences in Convalescent COVID-19 Patients
    Florian Bieberich, Rodrigo Vazquez-Lombardi, A. Yermanos, Roy A. Ehling, Derek M. Mason, Bastian Wagner, Edo Kapetanovic, Raphaël B. Di Roberto, Cédric R. Weber, M. Savic et al. · 2021 · bioRxiv
  26. Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative
    Sameer Kumar Malladi, Unnatiben Rajeshbhai Patel, Raju S Rajmani, Randhir Singh, Suman Pandey, Sahil Kumar, Sara Khaleeq, Petrus Jansen van Vuren, Shane Riddell, Sarah Goldie et al. · 2021 · ACS Infectious Diseases
  27. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
    Ya-Ping Sun, Mitchell Ho · 2020 · Antibody Therapeutics
  28. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
    Hejun Liu, Nicholas C. Wu, M. Yuan, S. Bangaru, J. Torres, T. Caniels, J. van Schooten, Xue-Yong Zhu, C. D. Lee, P. Brouwer et al. · 2020 · Immunity
  29. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
    Yubin Liu, Ziyi Wang, Xinyu Zhuang, Shengnan Zhang, Zhicheng Chen, Yan Zou, Jie Sheng, Tianpeng Li, Wanbo Tai, Jinfang Yu et al. · 2023 · Nature Communications
  30. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees
    Takeshi Inoue, Ryo Shinnakasu, C. Kawai, Hiromi Yamamoto, S. Sakakibara, Chikako Ono, Yumi Itoh, T. Terooatea, Kazuo Yamashita, Toru Okamoto et al. · 2022 · Journal of Experimental Medicine
  31. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters
    Lei Li, Yoshikazu Honda-Okubo, Jeremy Baldwin, R. Bowen, H. Bielefeldt-Ohmann, N. Petrovsky · 2022 · Vaccine
  32. Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions
    M. H. Cheng, James M. Krieger, Anupam Banerjee, Yufei Xiang, B. Kaynak, Yi Shi, M. Arditi, I. Bahar · 2022 · iScience
  33. A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies
    Patthara Kongsuphol, Huan Jia, Hoi-Lok Cheng, Yue Gu, B. Shunmuganathan, Ming-Wei Chen, Sing-Mei Lim, S. Ng, P. Tambyah, H. Nasir et al. · 2021 · Communications Medicine
  34. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients
    Li-Guo Zhu, Xin Xu, Bao-Li Zhu, Xi-Ling Guo, Ke Xu, Ci Song, Jian-Guang Fu, Hui-Yan Yu, Xiaoxiao Kong, Jiefu Peng et al. · 2021 · Microbiology spectrum
  35. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects
    S. Lusvarghi, Wei Wang, Rachel Herrup, S. Neerukonda, R. Vassell, Lisa Bentley, A. Eakin, Karl J. Erlandson, C. Weiss · 2021 · bioRxiv
  36. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
    Fiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, David Ross Darley, Deepti Pilli, Daniele Vitale, Vera Merheb, Fiona X. Z. Lee, Philip Cunningham, Gregory J. Walker et al. · 2021 · PLoS Medicine
  37. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection
    Emma S. Winkler, P. Gilchuk, Jin-Sheng Yu, Adam Leitman Bailey, Rita E. Chen, Seth J. Zost, Hyesun Jang, Ying Huang, James D. Allen, J. Case et al. · 2020 · bioRxiv
  38. Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
    Hanke, Leo, Sheward, Daniel J., Pankow, Alec, Vidakovics, Laura Perez, Karl, Vivien, Kim, Changil, Urgard, Egon, Smith, Natalie L., Astorga-Wells, Juan, Ekström, Simon et al. · 2022 · Science Advances
  39. Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies
    Hanke, Leo, Sheward, Daniel J., Pankow, Alec, Vidakovics, Laura Perez, Karl, Vivien, Kim, Changil, Urgard, Egon, Smith, Natalie L., Astorga-Wells, Juan, Ekström, Simon et al. · 2021
  40. Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
    Ozer, Egon A., Simons, Lacy M., Adewumi, Olubusuyi M., Fowotade, Adeola A., Omoruyi, Ewean C., Adeniji, Johnson A., Dean, Taylor J., Zayas, Janet, Bhimalli, Pavan P., Ash, Michelle K. et al. · 2021
  41. Inhalable materials and biologics for lung defence and drug delivery
    Savannah Weihang Zhang, David A. Edwards, R. Langer, K. Cheng · 2025 · Nature Reviews Materials
  42. Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine
    Ben S. Ou, Olivia Saouaf, Jerry Yan, Theodora U. J. Bruun, J. Baillet, Xue-Ting Zhou, N. King, E. Appel · 2023 · bioRxiv
  43. Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike
    Diego M. Cantoni, Matthew J Murray, Mphatso D. Kalemera, Samuel J. Dicken, Lenka Stejskal, Georgina Brown, Spyros Lytras, Jonathon D. Coey, James Patrick McKenna, Stephen Bridgett et al. · 2022 · EMBO Reports
  44. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
    Maddalena Marconato, Irène A. Abela, Anthony Hauser, Magdalena Schwarzmüller, Rheliana Katzensteiner, Dominique L. Braun, Selina Epp, Annette Audigé, Jacqueline Weber, Peter Rusert et al. · 2022 · Journal of Clinical Investigation
  45. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
    L. Karpenko, A. P. Rudometov, S. V. Sharabrin, D. Shcherbakov, M. B. Borgoyakova, S. Bazhan, E. Volosnikova, N. Rudometova, L. A. Orlova, I. Pyshnaya et al. · 2021 · Vaccines
  46. Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
    N. Mishra, Sanjeev Kumar, Swarandeep Singh, Tanu Bansal, N. Jain, Sumedha Saluja, Rajesh Kumar, S. Bhattacharyya, J. Palanichamy, R. Mir et al. · 2020 · bioRxiv
  47. Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants
    Mengfei Chen, Andrew S Pekosz, Jason Villano, Wenjuan Shen, Ruifeng Zhou, Heather M. Kulaga, Zhexuan Li, Amy K. Smith, Asiana Gurung, Sarah E. Beck et al. · 2024 · Journal of Clinical Investigation
  48. Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa
    E. du Bruyn, C. Stek, Remi Daroowala, Q. Said-Hartley, M. Hsiao, Georgia Schafer, R. Goliath, F. Abrahams, A. Jackson, S. Wasserman et al. · 2023 · Nature Communications
  49. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
    Wei Shi, Lingshu Wang, Tongqing Zhou, Mallika Sastry, Eun Sung Yang, Yi Zhang, Man Chen, Xuejun Chen, Misook Choe, Adrian Creanga et al. · 2022 · Structure
  50. A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies
    F. Ferrara, M. F. Erasmus, S. D'Angelo, Camila Leal-Lopes, Andre A. R. Teixeira, A. Choudhary, W. Honnen, D. Calianese, De-Li Huang, Linghang Peng et al. · 2022 · Nature Communications
  51. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
    Zhen-Lin Yang, Yulu Wang, Yu-jia Jin, Yuan-Fei Zhu, Yan-Ling Wu, Cheng Li, Yu Kong, Wen-Ping Song, Xiaolong Tian, Wuqiang Zhan et al. · 2021 · Signal Transduction and Targeted Therapy
  52. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
    Ze-Zhong Liu, Wei Xu, Zhenguo Chen, Wang-Jun Fu, Wuqiang Zhan, Yi-Dan Gao, Jie Zhou, Yunjiao Zhou, Jian-Bo Wu, Qian Wang et al. · 2021 · Protein & Cell
  53. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
    D. Fu, Guang-Shun Zhang, Yuhui Wang, Zheng Zhang, Heng-Rui Hu, S. Shěn, Jun Wu, Bo Li, Xin Li, Yao-Hui Fang et al. · 2021 · PLoS Biology
  54. Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
    R. Rouet, Ohan Mazigi, G. Walker, D. Langley, M. Sobti, P. Schofield, Helen Lenthall, J. Jackson, Stephanie Ubiparipovic, J. Henry et al. · 2020 · bioRxiv
  55. Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein
    C. Garrett Rappazzo, Ching-Lin Hsieh, Scott A. Rush, Emma S. Esterman, Teresa Delgado, James C. Geoghegan, Anna Z. Wec, Mrunal Sakharkar, Vicente Más, Jason S. McLellan et al. · 2022 · Immunity
  56. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys
    Heng Li, Lei Guo, Hui-Wen Zheng, Jing Li, Xin Zhao, Jia-Qi Li, Yan Liang, Fengmei Yang, Yu-Rong Zhao, Jin-Ling Yang et al. · 2021 · Bioconjugate chemistry
  57. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · bioRxiv
  58. Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro
    Chuan Xu, Annie Wang, E. Hoskin, Carla Cugini, K. Markowitz, Theresa L. Chang, D. Fine · 2021 · Pathogens
  59. Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
    Yang Huang, Hui Sun, Hai Jing Yu, Shaowei Li, Qingbing Zheng, Ningshao Xia · 2020 · Antibody Therapeutics
  60. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak
    Zheng Zhang, Ji Chen, Jung-hua Wang, Qiao Gao, Zhu-Jun Ma, Shu-Rong Xu, Li Zhang, J. Cai, Wei-Chang Zhou · 2020 · Biotechnology progress (Print)
  61. The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera
    Steffen, Tara L., Stone, E. Taylor, Hassert, Mariah, Geerling, Elizabeth, Grimberg, Brian T., Espino, Ana M., Pantoja, Petraleigh, Climent, Consuelo, Hoft, Daniel F., George, Sarah L. et al. · 2020
  62. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology
  63. Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
    Frauke Muecksch, H. Wise, K. Templeton, Becky Batchelor, M. Squires, Kirsty McCance, L. Jarvis, K. Malloy, E. Furrie, C. Richardson et al. · 2022 · The Lancet Microbe
  64. A broad and potent neutralization epitope in SARS-related coronaviruses
    M. Yuan, Xue-Yong Zhu, Wan-ting He, Pan-Pan Zhou, C. Kaku, Tazio Capozzola, Connie Y Zhu, Xinye Yu, Hejun Liu, Wenli Yu et al. · 2022 · bioRxiv
  65. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
    Caroline Hirsch, Sarah J Valk, V. Piechotta, K. Chai, L. Estcourt, I. Monsef, S. Salomon, Eve Tomlinson, Maria Popp, E. Wood et al. · 2021 · Cochrane Database of Systematic Reviews
  66. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
    Raju Sunagar, Amit Singh, Sudeep Kumar · 2023 · Vaccines
  67. Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection
    D. Vanover, C. Zurla, H. Peck, Nichole Orr-Burks, J. Joo, J. Murray, Nathan Holladay, Ryan A Hobbs, Younghun Jung, Lorena C S Chaves et al. · 2022 · Advancement of science
  68. Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
    Chang-ki Oh, Tomohiro Nakamura, N. Beutler, Xu Zhang, J. Piña-Crespo, M. Talantova, S. Ghatak, D. Trudler, Lauren N. Carnevale, S. Mckercher et al. · 2022 · Nature Chemical Biology
  69. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
    William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl · 2022 · BioDrugs
  70. Efficient evolution of human antibodies from general protein language models and sequence information alone
    Brian L. Hie, Duo Xu, Varun R. Shanker, Theodora U. J. Bruun, P. Weidenbacher, Shao-Geng Tang, Peter S. Kim · 2022 · bioRxiv
  71. Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2
    Kristen A. Rodrigues, Sergio A. Rodriguez-Aponte, N. C. Dalvie, J. Lee, Wuhbet D. Abraham, D. Carnathan, Luis E Jimenez, Julia T. Ngo, Jason Y. H. Chang, Zeli Zhang et al. · 2021 · Science Advances
  72. COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
    Saptarshi Sinha, Vanessa Castillo, C. Espinoza, C. Tindle, Ayden G. Fonseca, J. Dan, Gajanan D. Katkar, Soumita Das, D. Sahoo, P. Ghosh · 2021 · bioRxiv
  73. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein
    Shijian Zhang, E. Go, Haitao Ding, Saumya Anang, J. Kappes, Heather Desaire, J. Sodroski · 2021 · bioRxiv
  74. Durable SARS-CoV-2 B cell immunity after mild or severe disease
    Clinton O. Ogega, Nicole Skinner, Paul W. Blair, Han-Sol Park, Kirsten E. Littlefield, Abhinaya Ganesan, Santosh Dhakal, Pranay Ladiwala, Annukka A.R. Antar, Stuart C. Ray et al. · 2021 · Journal of Clinical Investigation
  75. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
    Shi-On A. Lim, Josef A. Gramespacher, Katarina Pance, Nicholas J. Rettko, Paige E. Solomon, Jing Jin, Irene Lui, Susanna K. Elledge, Jia Liu, Colton J. Bracken et al. · 2021 · mAbs
  76. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
    Laetitia E Misson Mindrebo, Hejun Liu, G. Ozorowski, Quoc Tran, J. Woehl, Irene S. Khalek, Jessica M. Smith, Shawn Barman, Fang-Zhu Zhao, Celina Keating et al. · 2023 · Proceedings of the National Academy of Sciences of the United States of America
  77. Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant
    Wan-Bo Tai, Ben-Jie Chai, Sheng-Jun Feng, X. Zhuang, Jun Ma, Mujia Pang, Lin Pan, Ziqing Yang, Ming-Yao Tian, G. Cheng · 2022 · bioRxiv
  78. Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses
    Victor C. Yin, Szu-Hsueh Lai, T. Caniels, P. Brouwer, Mitch Brinkkemper, Y. Aldon, Hejun Liu, M. Yuan, Ian A. Wilson, R. Sanders et al. · 2021 · ACS Central Science
  79. Versatile and rapid microfluidics-assisted antibody discovery
    Ramona Gaa, Emmanuel Menang-Ndi, Shruti Pratapa, Christine Nguyen, Satyendra Kumar, Achim Doerner · 2021 · mAbs
  80. SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses
    R. Suhandynata, N. Bevins, J. Tran, De-Li Huang, M. Hoffman, Kyle Lund, M. Kelner, R. Mclawhon, S. Gonias, D. Nemazee et al. · 2021 · The Journal of Applied Laboratory Medicine
  81. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
    Kaho Shionoya, Masako Yamasaki, Shoya Iwanami, Yusuke Ito, S. Fukushi, Hirofumi Ohashi, Wakana Saso, Tomohiro Tanaka, S. Aoki, Kouji Kuramochi et al. · 2021 · Frontiers in Microbiology
  82. SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
    Marco Mandolesi, D. Sheward, L. Hanke, Jun-Jie Ma, Pradeepa Pushparaj, Laura Perez Vidakovics, Changil Kim, M. Ádori, K. Lenart, K. Loré et al. · 2021 · Cell Reports Medicine
  83. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
    Aditi Mohan, Venkatesh Anand Iyer, Dharmender Kumar, Lalit Batra, Praveen Dahiya · 2023 · Life
  84. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
    Ying-Dan Wang, Mei-Qin Liu, Yaping Shen, Yunping Ma, Xiang Li, Yuan-Yuan Zhang, Mei Liu, Xing-Lou Yang, Jun Chen, R. Yan et al. · 2022 · Cell Discovery
  85. Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers
    K. Saker, V. Escuret, V. Pitiot, A. Massardier‐Pilonchery, S. Paul, Bouchra Mokdad, C. Langlois-Jacques, M. Rabilloud, David Goncalves, N. Fabien et al. · 2021 · Journal of Clinical Microbiology
  86. One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
    I. Francino-Urdaniz, Paul J. Steiner, Monica B Kirby, Fang-Zhu Zhao, Cyrus M. Haas, Shawn Barman, Emily R. Rhodes, Alison C. Leonard, Linghang Peng, K. Sprenger et al. · 2021 · Cell Reports
  87. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
    Wan-ting He, M. Yuan, Sean Callaghan, Rami Musharrafieh, G. Song, Murillo Silva, N. Beutler, W. Lee, Peter Yong, J. Torres et al. · 2021 · bioRxiv
  88. Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis
    Rong-Sui Gao, Wenhong Zu, Yang Liu, Jun-Hua Li, Zeyao Li, Yanling Wen, Hai-Yan Wang, Jing Yuan, Lin Cheng, Shengyuan Zhang et al. · 2021 · Virulence
  89. Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19
    M. Iglesias, P. Butrón, Iván Torre-Villalvazo, Erik A. Torre-Anaya, J. Sierra-Madero, J. J. Rodríguez-Andoney, A. Tovar-Palacio, A. Zentella-Dehesa, G. Dominguez-Cherit, T. Rodríguez-Reyna et al. · 2021 · Aging and Disease
  90. Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
    Matthew J Murray, Megan McIntosh, Claire E. Atkinson, Tabitha W. Mahungu, Edward Wright, Wendy Chatterton, Michael Gandy, Matthew B. Reeves · 2021 · Journal of Infection
  91. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency
    K. Honjo, Ronnie M. Russell, Ran Li, Wei-Min Liu, R. Stoltz, E. Tabengwa, Yu-Tao Hua, L. Prichard, A. Kornbrust, S. Sterrett et al. · 2020 · Cell Reports Medicine
  92. Therapeutic potential of mesenchymal stem cell‐derived extracellular vesicles in SARS‐CoV‐2 and H1N1 influenza‐induced acute lung injury
    Jun-Ho Lee, H. Jeon, J. Lötvall, Byong Seung Cho · 2024 · Journal of Extracellular Vesicles
  93. Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants
    Michael Korenkov, Matthias Zehner, Hadas Cohen‐Dvashi, Aliza Borenstein-Katz, Lisa Kottege, Hanna Janicki, Kanika Vanshylla, Timm Weber, Henning Gruell, Manuel Koch et al. · 2023 · Immunity
  94. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort
    Dominik Menges, Kyra D. Zens, Tala Ballouz, Nicole Caduff, Daniel Llanas-Cornejo, Hélène Eloise Aschmann, Anja Domenghino, Céline Pellaton, Matthieu Perreau, Craig W. Fenwick et al. · 2022 · Nature Communications
  95. An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
    Yan Fang, Pengcheng Sun, Xuping Xie, Mingjian Du, Fenghe Du, Jianfeng Ye, Birte Kalveram, Jessica A. Plante, Kenneth S. Plante, Bo Li et al. · 2022 · Science Immunology
  96. Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron
    Hejun Liu, Chengzi I. Kaku, Ge Song, Meng Yuan, Raiees Andrabi, Dennis R. Burton, Laura M. Walker, Ian A. Wilson · 2022 · Communications Biology
  97. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort
    Shihan Zhang, Ke Xu, Chu-Chu Li, Lu Zhou, Xiaoxiao Kong, Jiefu Peng, F. Zhu, C. Bao, Hui Jin, Qiang Gao et al. · 2022 · Frontiers in Immunology
  98. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
    Naveenchandra Suryadevara, Andrea R. Shiakolas, Laura A. VanBlargan, E. Binshtein, Rita E. Chen, J. Case, Kevin J. Kramer, Erica C. Armstrong, Luke Myers, Andrew Trivette et al. · 2022 · bioRxiv
  99. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination
    Marios Koutsakos, Wen Shi Lee, Adam K Wheatley, Stephen J Kent, Jennifer A. Juno · 2021 · Journal of Leukocyte Biology
  100. SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
    A. Kuzmina, Seraj Wattad, Y. Khalaila, A. Ottolenghi, B. Rosental, Stanislav Engel, Elli Rosenberg, R. Taube · 2021 · iScience